137 related articles for article (PubMed ID: 9783492)
41. [Effect of twelve-month combined therapy with perindopril and indapamide on the level of blood pressure and left ventricular hypertrophy in patients with hypertensive disease].
Timofeeva LA; Alekhin MN; Ugriumov MO; Chumakova OS; Larina VN; Sidorenko BA
Kardiologiia; 2006; 46(3):30-4. PubMed ID: 16710252
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Tolerability of Fixed-Dose Combination Perindopril/Indapamide in Hypertensive Patients with a History of Stroke or Transient Ischemic Attack: PICASSO Trial.
Dézsi CA; Farsang C;
Adv Ther; 2018 May; 35(5):644-654. PubMed ID: 29748913
[TBL] [Abstract][Full Text] [Related]
43. Blood pressure lowering in patients with cerebrovascular disease: results of the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) pilot phase.
Neal B; Anderson C; Chalmers J; MacMahon S; Rodgers A
Clin Exp Pharmacol Physiol; 1996 May; 23(5):444-6. PubMed ID: 8713688
[TBL] [Abstract][Full Text] [Related]
44. A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS).
Stumpe KO; Overlack A
Am J Cardiol; 1993 Jun; 71(17):32E-37E. PubMed ID: 8328365
[TBL] [Abstract][Full Text] [Related]
45. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature.
Liu L; Wang Z; Gong L; Zhang Y; Thijs L; Staessen JA; Wang J
Hypertens Res; 2009 Nov; 32(11):1032-40. PubMed ID: 19798097
[TBL] [Abstract][Full Text] [Related]
46. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Hansson L
J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
[TBL] [Abstract][Full Text] [Related]
47. Combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide activate postnatal vasculogenesis in spontaneously hypertensive rats.
You D; Cochain C; Loinard C; Vilar J; Mees B; Duriez M; Lévy BI; Silvestre JS
J Pharmacol Exp Ther; 2008 Jun; 325(3):766-73. PubMed ID: 18309090
[TBL] [Abstract][Full Text] [Related]
48. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects.
Amar J; Ruidavets JB; Peyrieux JC; Mallion JM; Ferrières J; Safar ME; Chamontin B
Hypertension; 2005 Jul; 46(1):151-5. PubMed ID: 15956115
[TBL] [Abstract][Full Text] [Related]
49. What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension?
Waeber B
Expert Opin Pharmacother; 2005 Oct; 6(13):2291-9. PubMed ID: 16218889
[TBL] [Abstract][Full Text] [Related]
50. Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study.
Whitlock G; MacMahon S; Anderson C; Neal B; Rodgers A; Chalmers J
Clin Exp Hypertens; 1997; 19(5-6):843-55. PubMed ID: 9247759
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study.
Holzgreve H; Risler T; Trenkwalder P
Curr Med Res Opin; 2006 Sep; 22(9):1849-58. PubMed ID: 16968588
[TBL] [Abstract][Full Text] [Related]
52. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
53. Progress in reducing the burden of stroke.
Chalmers J; Chapman N
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1091-5. PubMed ID: 11903323
[TBL] [Abstract][Full Text] [Related]
54. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease.
PROGRESS Collaborative Group
Eur Heart J; 2003 Mar; 24(5):475-84. PubMed ID: 12633548
[TBL] [Abstract][Full Text] [Related]
55. Perindopril + indapamide: new preparation. Simple trick.
Prescrire Int; 1999 Dec; 8(44):172-5. PubMed ID: 11503814
[TBL] [Abstract][Full Text] [Related]
56. [Vascular impact of anti-hypertensive treatment and renal protection].
Mogensen CE
Curr Med Res Opin; 2005; 21 Suppl 5():S23-8. PubMed ID: 16197649
[TBL] [Abstract][Full Text] [Related]
57. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Hansson L; Lindholm LH; Niskanen L; Lanke J; Hedner T; Niklason A; Luomanmäki K; Dahlöf B; de Faire U; Mörlin C; Karlberg BE; Wester PO; Björck JE
Lancet; 1999 Feb; 353(9153):611-6. PubMed ID: 10030325
[TBL] [Abstract][Full Text] [Related]
58. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
ADVANCE Management Committee
Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
[TBL] [Abstract][Full Text] [Related]
59. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
[TBL] [Abstract][Full Text] [Related]
60. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial.
Keenan K; Hayen A; Neal BC; Irwig L
BMJ; 2009 Apr; 338():b1492. PubMed ID: 19406886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
